Exhibit 99.4

ASML — Summary IFRS Consolidated Income Statements ¹

	Three months ended,
(in thousands EUR)	Mar 30, 2008			Mar 29, 2009
Net system sales		819,986			101,100
Net service and field option sales		99,222			82,525
Total net sales		919,208			183,625
Cost of sales		561,687			196,360
Gross profit (loss) on sales		357,521			(12,735	)
Research and development costs, net of credits		82,723			78,025
Selling, general and administrative costs		57,696			41,968
Operating income (loss)		217,102			(132,728	)
Interest income		3,575			3,261
Income (loss) before income taxes		220,677			(129,467	)
(Provision for) benefit from income taxes		(54,217	)		21,692
Net income (loss)		166,460			(107,775	)

ASML — Summary IFRS Consolidated Balance Sheets ¹

(in thousands EUR)	Dec 31, 2008		Mar 29, 2009
ASSETS
Property, plant and equipment		550,921		596,069
Goodwill		139,626		148,415
Other intangible assets		289,530		306,082
Deferred tax assets		225,544		244,609
Finance receivables		31,030		29,250
Derivative financial instruments		53,206		69,986
Other assets		29,449		14,177
Total non-current assets		1,319,306		1,408,588
Inventories		999,150		936,770
Current tax assets		87,560		—
Derivative financial instruments		39,240		33,580
Finance receivables		6,225		6,193
Accounts receivable		463,273		291,644
Other assets		170,680		186,004
Cash and cash equivalents		1,109,184		1,151,010
Total current assets		2,875,312		2,605,201
Total assets		4,194,618		4,013,789
EQUITY AND LIABILITIES
Equity		2,188,743		2,007,676
Long-term debt		661,483		671,492
Derivative financial instruments		19,743		1,566
Deferred and other tax liabilities		260,360		258,081
Provisions		15,495		16,955
Accrued liabilities and other liabilities		50,293		46,678
Total non-current liabilities		1,007,374		994,772
Accounts payable		193,690		165,252
Accrued liabilities and other liabilities		732,043		789,796
Current tax liabilities		20,039		11,161
Derivative financial instruments		48,051		40,650
Provisions		4,678		4,482
Total current liabilities		998,501		1,011,341
Total equity and liabilities		4,194,618		4,013,789

ASML — Summary IFRS Consolidated Statements of Cash Flows ¹

	Three months ended,
(in thousands EUR)	Mar 30, 2008			Mar 29, 2009
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)		166,460			(107,775	)
Depreciation and amortization		45,218			63,644
Loss on disposals of property, plant and equipment		1,103			2,639
Impairment charges		1,551			2,592
Share-based payments		3,404			3,512
Allowance for doubtful debts		540			(13	)
Allowance for obsolete inventory		20,766			22,135
Change in assets and liabilities		73,840			137,312
Net cash provided by operating activities		312,882			124,046
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(55,032	)		(43,903	)
Proceeds from sale of property, plant and equipment		—			1,200
Purchases of intangible assets		(45,526	)		(40,291	)
Net cash used in investing activities		(100,558	)		(82,994	)
CASH FLOWS FROM FINANCING ACTIVITIES
Purchase of shares in conjunction with share-based payment plans		(87,605	)		—
Net proceeds from issuance of shares and stock options		2,975			102
Redemption and / or repayment of debt		—			(1,735	)
Net cash provided by (used in) financing activities		(84,630	)		(1,633	)
Net cash flows		127,694			39,419
Effect of changes in exchange rates on cash		(2,186	)		2,407
Net increase in cash & cash equivalents		125,508			41,826
					—

ASML — Quarterly Summary IFRS Consolidated Income Statements ¹

	Three months ended,
	Mar 30,			Jun 29,		Sep 28,			Dec 31,			Mar 29,
(in millions EUR)	2008			2008		2008			2008			2009
Net system sales		820.0			725.6		590.7			380.5			101.1
Net service and field option sales		99.2			118.6		105.8			113.3			82.5
Total net sales		919.2			844.2		696.5			493.8			183.6
Cost of sales		561.7			525.3		452.7			476.5			196.3
Gross profit (loss) on sales		357.5			318.9		243.8			17.3			(12.7	)
Research and development costs, net of credits		82.7			87.1		88.6			95.8			78.0
Selling, general and administrative costs		57.7			55.3		52.2			47.7			42.0
Operating income (loss)		217.1			176.5		103.0			(126.2	)		(132.7	)
Interest income		3.6			5.0		6.6			2.8			3.2
Income (loss) before income taxes		220.7			181.5		109.6			(123.4	)		(129.5	)
(Provision for) benefit from income taxes		(54.2	)		29.0		(27.0	)		40.8			21.7
Net income (loss)		166.5			210.5		82.6			(82.6	)		(107.8	)

ASML — Quarterly Summary IFRS Consolidated Balance Sheets ¹

	Mar 30,		Jun 29,		Sep 28,		Dec 31,		Mar 29,
(in millions EUR)	2008		2008		2008		2008		2009
ASSETS
Property, plant and equipment		401.4		458.1		503.1		550.9		596.1
Goodwill		127.2		127.3		137.3		139.6		148.4
Other intangible assets		238.0		260.5		281.3		289.5		306.1
Deferred tax assets		213.3		238.4		228.6		225.6		244.6
Finance receivables		—		—		30.7		31.0		29.2
Derivative financial instruments		47.7		1.4		12.3		53.2		70.0
Other assets		31.8		32.0		32.6		29.5		14.2
Total non-current assets		1,059.4		1,117.7		1,225.9		1,319.3		1,408.6
Inventories		1,152.0		1,130.2		1,134.0		999.1		936.8
Current tax assets		—		—		—		87.6		—
Derivative financial instruments		36.5		46.6		21.0		39.2		33.6
Finance receivables		0.2		0.2		7.4		6.2		6.2
Accounts receivable		741.3		516.7		536.1		463.3		291.6
Other assets		202.4		185.9		210.6		170.7		186.0
Cash and cash equivalents		1,397.1		1,360.9		1,313.0		1,109.2		1,151.0
Total current assets		3,529.5		3,240.5		3,222.1		2,875.3		2,605.2
Total assets		4,588.9		4,358.2		4,448.0		4,194.6		4,013.8
EQUITY AND LIABILITIES
Equity		2,121.8		2,242.6		2,314.7		2,188.7		2,007.7
Long-term debt		609.1		585.6		591.0		661.5		671.5
Derivative financial instruments		—		11.2		0.9		19.7		1.6
Deferred and other tax liabilities		282.9		260.2		256.9		260.4		258.1
Provisions		—		—		—		15.5		16.9
Accrued liabilities and other liabilities		7.2		7.4		7.8		50.3		46.7
Total non-current liabilities		899.2		864.4		856.6		1,007.4		994.8
Accounts payable		479.6		267.2		271.0		193.7		165.2
Accrued liabilities and other liabilities		957.7		910.8		948.1		732.0		789.8
Current tax liabilities		111.5		50.8		42.4		20.0		11.2
Derivative financial instruments		19.1		22.4		15.2		48.1		40.6
Provisions		—		—		—		4.7		4.5
Total current liabilities		1,567.9		1,251.2		1,276.7		998.5		1,011.3
Total equity and liabilities		4,588.9		4,358.2		4,448.0		4,194.6		4,013.8

ASML — Quarterly Summary IFRS Consolidated Statements of Cash Flows ¹

	Three months ended,
	Mar 30,			Jun 29,			Sep 28,			Dec 31,			Mar 29,
(in millions EUR)	2008			2008			2008			2008			2009
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)		166.5			210.5			82.6			(82.6	)		(107.8	)
Depreciation and amortization		45.2			44.7			50.1			57.2			63.6
Loss on disposals of property, plant and equipment		1.1			1.3			1.4			0.4			2.7
Impairment charges		1.6			—			0.6			41.2			2.6
Share-based payments		3.4			2.9			3.6			3.0			3.5
Allowance for doubtful debts		0.5			(0.6	)		(0.2	)		0.5			—
Allowance for obsolete inventory		20.8			11.8			21.3			85.8			22.1
Change in assets and liabilities		73.8			(91.6	)		(99.0	)		(215.3	)		137.3
Net cash provided by (used in) operating activities		312.9			179.0			60.4			(109.8	)		124.0
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(55.0	)		(65.5	)		(68.3	)		(71.1	)		(43.9	)
Proceeds from sale of property, plant and equipment		—			—			—			—			1.2
Purchases of intangible assets		(45.6	)		(43.0	)		(41.4	)		(49.4	)		(40.3	)
Net cash used in investing activities		(100.6	)		(108.5	)		(109.7	)		(120.5	)		(83.0	)
CASH FLOWS FROM FINANCING ACTIVITIES
Purchase of shares in conjunction with share-based payment plans		(87.6	)		—			—			—			—
Dividend paid		—			(107.4	)		(0.4	)		—			—
Net proceeds from issuance of shares and stock options		3.0			0.5			1.4			6.5			0.1
Net proceeds from other long-term debt		—			—			—			19.9			—
Redemption and/or repayment of debt		—			—			(1.3	)		(1.1	)		(1.7	)
Net cash provided by (used in) financing activities		(84.6	)		(106.9	)		(0.3	)		25.3			(1.6	)
Net cash flows		127.7			(36.4	)		(49.6	)		(205.0	)		39.4
Effect of changes in exchange rates on cash		(2.2	)		0.2			1.7			1.2			2.4
Net increase (decrease) in cash & cash equivalents		125.5			(36.2	)		(47.9	)		(203.8	)		41.8

ASML — Notes to the Summary IFRS Consolidated Financial Statements

Basis of Presentation

ASML has prepared the accompanying summary consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the EU – accounting principles generally accepted in the Netherlands for companies quoted on Euronext Amsterdam. Further disclosures, as required under IFRS in annual reports and interim reporting (IAS 34), are not included. The accompanying consolidated financial statements are stated in thousands of euros (‘EUR’), except otherwise indicated.

For internal and external reporting purposes, ASML follows accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP is ASML’s primary accounting standard for the Company’s setting of financial and operational performance targets.

Principles of consolidation

The consolidated financial statements include the accounts of ASML Holding N.V. and all of its majority-owned subsidiaries. Subsidiaries are all entities over which ASML has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. All intercompany profits, balances and transactions have been eliminated in the consolidation.

Use of estimates

The preparation of ASML’s consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities on the balance sheet dates and the reported amounts of revenue and expense during the reported periods. Actual results could differ from those estimates.

Recognition of revenues

In general, ASML recognizes the revenue from the sale of a system upon shipment and the revenue from the installation of a system upon completion of that installation at the customer site. Each system undergoes, prior to shipment, a “Factory Acceptance Test” in our clean room facilities, effectively replicating the operating conditions that will be present on the customer’s site, in order to verify whether the system will meet its standard specifications and any additional technical and performance criteria agreed with the customer. A system is shipped, and revenue is recognized, only after all specifications are met and customer sign-off is received or waived. Although each system’s performance is re-tested upon installation at the customer’s site, we have never failed to successfully complete installation of a system at a customer’s premises.

A portion of our revenue is derived from contractual arrangements with our customers that have multiple deliverables, such as installation and training services, prepaid service contracts and prepaid extended optic warranty contracts. The revenue relating to the undelivered elements of the arrangements is deferred until delivery of these elements. Revenue from installation and training services is recognized when the services are completed. Revenue from prepaid service contracts and prepaid extended optic warranty contracts is recognized over the term of the contract.

ASML – Reconciliation U.S. GAAP – IFRS ¹

Net income

	Three months ended,
(in thousands EUR)	Mar 30, 2008			Mar 29, 2009
Net income under U.S. GAAP		145,123			(117,191	)
Share-based payments (see Note 1)		(762	)		(499	)
Capitalization of development costs (see Note 2)		21,681			11,515
Income taxes (see Note 3)		418			(1,600	)
Net income under IFRS		166,460			(107,775	)

Shareholders’ equity

	Mar 30,			Jun 29,			Sep 28,			Dec 31,			Mar 29,
(in thousands EUR)	2008			2008			2008			2008			2009
Shareholders’ equity under U.S. GAAP		1,958,159			2,060,575			2,122,848			1,988,769			1,795,951
Share-based payments (see Note 1)		(3,420	)		(3,266	)		(7,904	)		(6,537	)		(7,088	)
Capitalization of development costs (see Note 2)		157,900			176,818			193,780			201,717			215,452
Income taxes (see Note 3)		9,186			8,478			5,969			4,794			3,361
Shareholders’ equity under IFRS		2,121,825			2,242,605			2,314,693			2,188,743			2,007,676

Notes to the reconciliation from U.S. GAAP to IFRS

Note 1 Share-based Payments

Under IFRS, ASML applies IFRS 2, “Share-based Payments” beginning from January 1, 2004. In accordance with IFRS 2, ASML records as an expense the fair value of its share-based payments with respect to stock options and stock granted to its employees after November 7, 2002. Under IFRSs, a deferred tax asset is computed on the basis of the tax deduction for the share-based payments every period under the applicable tax law and is recognized to the extent it is probable that future taxable profit will be available against which these deductible temporary differences will be utilized. Therefore, changes in the Company’s share price do affect the deferred tax asset at period-end and result in adjustments to the deferred tax asset.

As of January 1, 2006, ASML applies SFAS No. 123(R) “Share-Based Payment” which is a revision of SFAS No.123. SFAS 123(R) requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant-date fair value of those instruments. FAS 123(R)’s general principle is that a deferred tax asset is established as the Company recognizes compensation costs for commercial purposes for awards that are expected to result in a tax deduction under existing tax law. Under U.S. GAAP, the deferred tax recorded on share-based compensation is computed on the basis of the expense recognized in the financial statements. Therefore, changes in the Company’s share price do not affect the deferred tax asset recorded in the Company’s financial statements.

Note 2 Capitalization of development costs

Under IFRS, ASML applies IAS 38, “Intangible Assets”. In accordance with IAS 38, capitalized development expenditures are amortized over the expected useful life of the related product generally ranging between one and three years. Amortization starts when the developed product is ready for volume production. In 2008, we recognized an impairment charge for an amount of EUR 18.3 million.

Under U.S. GAAP, ASML applies SFAS No. 2, “Accounting for Research and Development Costs”. In accordance with SFAS No. 2, ASML charges costs relating to research and development to operating expense as incurred.

Note 3 Income taxes

Under IFRS, ASML applies IAS 12, “Income Taxes” beginning from January 1, 2005. In accordance with IAS 12 unrealized net income resulting from intercompany transactions that are eliminated from the carrying amount of assets on consolidation, give rise to a temporary difference for which deferred taxes must be recognized on consolidation. The deferred taxes are calculated based on the tax rate applicable in the purchaser’s tax jurisdiction.

Under U.S. GAAP, the elimination of unrealized net income from intercompany transactions that are eliminated from the carrying amount of assets on consolidation, give rise to a temporary difference for which prepaid taxes must be recognized on consolidation. Contrary to IFRS, the prepaid taxes under U.S. GAAP are calculated based on the tax rate applicable in the seller’s tax jurisdiction.

“Safe Harbor” Statement under the US Private Securities Litigation Reform Act of 1995: the matters discussed in this document may include forward-looking statements, including statements made about our outlook, realization of backlog, IC unit demand, financial results, average sales price, gross margin and expenses. These forward looking statements are subject to risks and uncertainties including, but not limited to: economic conditions, credit market deterioration on consumer confidence which could affect our customers, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), competitive products and pricing, manufacturing efficiencies, new product development and customer acceptance of new products, ability to enforce patents and protect intellectual property rights, the outcome of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, changes in exchange rates and other risks indicated in the risk factors included in ASML’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission.

¹ All quarterly information in this press release is unaudited.